Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …

Uncontrolled cellular proliferation, mediated by dysregulation of the cell-cycle machinery
and activation of cyclin-dependent kinases (CDKs) to promote cell-cycle progression, lies at …

Lung neoplasms are the leading cause of death by cancer worldwide. Non-small cell lung
cancer (NSCLC) constitutes more than 80% of all lung malignancies and the majority of …

In patients with non-small cell lung cancer (NSCLC), the most frequent oncogene driver
mutation in Western countries is Kirsten rat sarcoma viral oncogene homolog (KRAS), and …

Damaged cells at risk of neoplastic transformation can be neutralized by apoptosis or
engagement of the senescence program, which induces permanent cell-cycle arrest and a …

Lung cancer is the most frequent cancer with an aggressive clinical course and high
mortality rates. Most cases are diagnosed at advanced stages when treatment options are …

KRAS mutations are the most frequent gain-of-function alterations in patients with lung
adenocarcinoma (LADC) in the Western world. Although they have been identified decades …

KRAS is the most frequent oncogene in non-small cell lung cancer (NSCLC), a molecular
subset characterized by historical disappointments in targeted treatment approaches such …

Cell senescence is a driver of ageing, frailty, age-associated disease and functional decline.
In oncology, tumour cell senescence may contribute to the effect of adjuvant therapies, as it …

The induction of senescence produces a stable cell cycle arrest in cancer cells, thereby
inhibiting tumor growth; however, the incomplete immune cell-mediated clearance of …